Abacus Life, Inc. (NASDAQ:ABL – Get Free Report) insider Sean Mcnealy sold 75,800 shares of the business’s stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $8.00, for a total value of $606,400.00. Following the sale, the insider now directly owns 12,361,500 shares of the company’s stock, valued at $98,892,000. This represents a 0.61 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Abacus Life Stock Performance
NASDAQ ABL opened at $7.54 on Wednesday. The company has a market capitalization of $638.48 million, a PE ratio of -41.89 and a beta of 0.13. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.29 and a current ratio of 1.29. Abacus Life, Inc. has a 52-week low of $7.07 and a 52-week high of $13.25. The company has a 50-day simple moving average of $8.37 and a 200 day simple moving average of $9.27.
Abacus Life (NASDAQ:ABL – Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.06. Abacus Life had a negative net margin of 11.65% and a positive return on equity of 12.88%. The company had revenue of $28.15 million during the quarter, compared to analyst estimates of $26.08 million. During the same quarter last year, the business posted $0.01 EPS. On average, research analysts predict that Abacus Life, Inc. will post 0.64 EPS for the current year.
Institutional Inflows and Outflows
Analysts Set New Price Targets
Several brokerages recently issued reports on ABL. B. Riley Financial reiterated a “buy” rating and set a $16.00 price target on shares of Abacus Life in a report on Friday, August 30th. Piper Sandler reiterated an “overweight” rating and issued a $13.00 target price (up previously from $12.00) on shares of Abacus Life in a report on Friday, November 8th. Northland Capmk raised shares of Abacus Life to a “strong-buy” rating in a research report on Thursday, October 24th. B. Riley upped their price objective on shares of Abacus Life from $16.00 to $17.00 and gave the stock a “buy” rating in a research report on Monday, November 25th. Finally, Northland Securities initiated coverage on shares of Abacus Life in a research report on Thursday, October 24th. They set an “outperform” rating and a $13.50 target price on the stock. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Abacus Life currently has a consensus rating of “Buy” and an average price target of $14.70.
Read Our Latest Analysis on Abacus Life
Abacus Life Company Profile
Abacus Life, Inc operates as an alternative asset manager specializing in life insurance products. It purchases life insurance policies from consumers seeking liquidity and manages policies over time via trading, holding, and/or servicing. The company was founded in 2004 and is based in Orlando, Florida.
Featured Articles
- Five stocks we like better than Abacus Life
- Learn Technical Analysis Skills to Master the Stock Market
- 5 Reasons DraftKings Stock Looks Promising in the New Year
- 3 Healthcare Dividend Stocks to Buy
- Cybersecurity Stocks: 1 Immediate Buy and 1 Dip Opportunity
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- The Next 2 AI Winners Have Triple-Digit Upside Potential
Receive News & Ratings for Abacus Life Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abacus Life and related companies with MarketBeat.com's FREE daily email newsletter.